United States Patent 10,016,396 (Dexmedetomidine IV Premixture): Scope, Claim Architecture, and US Landscape
US Patent 10,016,396 claims a ready-to-use intravenous (IV) liquid premix of dexmedetomidine (or its pharmaceutically acceptable salt) in sealed glass, with defined drug concentration ranges and product-quality constraints (notably stability in glass for at least five months). The claims also lock in formulation attributes (pH range, optional sodium chloride level), container/volume selections, salt form (including hydrochloride), and sterilization mode (terminal sterilization by autoclave).
What does the patent claim in plain scope terms?
Core claimed product
The independent claim (Claim 1) defines the invention as:
- Product type: liquid pharmaceutical composition for IV administration
- Drug: dexmedetomidine or pharmaceutically acceptable salt
- Concentration: about 0.005 μg/mL to about 50 μg/mL
- Packaging: disposed within a sealed glass container
- Use form: manufactured as a ready-to-use premixture that does not require reconstitution or dilution prior to patient administration
Key dependent-layer scope locks
Dependent claims narrow the independent claim along five axes: concentration, excipient composition, volume selection, stability performance in glass, chemical form (salt), pH window, and sterilization method.
What are the concentration and formulation bands actually claimed?
Dexmedetomidine concentration bands
The patent layers multiple concentration cut points, which function like “allowed embodiments” rather than a single narrow numeric point.
| Claim |
Dexmedetomidine (or salt) concentration (μg/mL) |
Claim role |
| 1 |
0.005 to 50 |
Broadest numeric window |
| 2 |
0.05 to 15 |
Narrow subset |
| 3 |
0.5 to 10 |
Narrow subset |
| 4 |
1 to 7 |
Narrow subset |
| 5 |
1 to 4 |
Narrowest numeric subset in the ladder |
Scope implication: Any IV liquid dexmedetomidine premix in sealed glass that meets Claim 1 concentration bounds and is supplied as a ready-to-use premixture (no dilution/reconstitution) falls within the numeric claim geometry even if later dependent limitations are not met.
Sodium chloride excipient
- Claim 6: sodium chloride at 0.01 to 2.0 weight %
- Claim 7: sodium chloride at about 0.9 weight %
Scope implication: If a competing product uses NaCl outside these bounds, it may avoid dependent Claims 6–7, but still potentially implicate Claim 1 if all other elements match.
Total volume selections
- Claim 8: total volume selected from 20 mL, 50 mL, 100 mL
Scope implication: Packaging volume is an explicit dependent limiter. A product that fits Claim 1 but uses a non-listed volume can avoid Claim 8 while remaining exposed to Claim 1.
What stability requirement constrains the product beyond composition?
Glass-container stability performance
- Claim 9: when stored in the glass container for at least five months, exhibits no more than about 2% decrease in dexmedetomidine concentration.
Scope implication: This is not a mere formulation suggestion. It creates a performance claim that can be used to attack both:
- non-complying formulations (even if concentrations and pH overlap), and
- product positioning where the label/spec claims stability inconsistent with “≤2% decrease” over five months.
Because the condition is tied to “stored in the glass container,” stability against container interactions is integral to infringement arguments.
What chemical form and pH ranges are claimed?
Salt form
- Claim 10: dexmedetomidine is formulated as a hydrochloride salt
Scope implication: This is a dependent claim. A competitor using a different pharmaceutically acceptable salt (or free base, if applicable to dexmedetomidine) may avoid Claim 10 while still facing Claim 1.
pH range
The pH limitations cascade:
- Claim 11: pH about 2 to about 10
- Claim 12: pH about 4 to about 8
- Claim 13: pH about 4.5 to about 8
- Claim 14: pH between about 4.5 and about 7
Scope implication: The independent claim does not require a specific pH window. That means pH can become a key differentiator only if the opponent must rely on dependent claims. The pH ladder also gives the patent owner multiple “landing zones” if infringement is contested on formulation margins.
How does sterilization method affect the claim boundary?
- Claim 15: composition is terminally sterilized
- Claim 16: terminal sterilized by autoclave
Scope implication: Sterilization method is a dependent limiter. A competitor using aseptic processing, filtration-only, or a terminal sterilization approach not matching “autoclave” could aim to avoid Claims 15–16 while still fitting Claim 1’s structural product definition.
What is the effective claim scope after combining all elements?
Infringement-relevant element checklist (Claims 1–16)
For exposure to the broadest claim (Claim 1), the product must satisfy all:
- IV liquid pharmaceutical composition
- Contains dexmedetomidine or pharmaceutically acceptable salt
- Concentration in 0.005 μg/mL to 50 μg/mL
- Sealed glass container
- Ready-to-use premixture with no reconstitution or dilution required before patient administration
Dependent claims then add constraints:
- concentration narrower (Claims 2–5),
- NaCl content (Claims 6–7),
- packaged volume equals one of 20/50/100 mL (Claim 8),
- stability in that glass container: ≤2% concentration drop after 5 months (Claim 9),
- hydrochloride salt (Claim 10),
- pH within one of listed windows (Claims 11–14),
- terminal sterilized (Claim 15),
- terminal sterilized by autoclave (Claim 16).
Practical commercial interpretations
From a product development and design-around perspective, the patent’s strongest “hard edges” are:
- ready-to-use premix without dilution/reconstitution, and
- sealed glass container, and
- stability in glass over five months with ≤2% loss.
Those features are harder to argue as incidental because they tie directly to product form and performance rather than only excipients or pH.
How to map the patent landscape in the US for dexmedetomidine IV premixes
Landscape segmentation framework
Even without asserting specific co-existing patents by number in the absence of a validated dataset in this record, the US patent landscape for dexmedetomidine IV products typically clusters into these buckets that matter for freedom-to-operate (FTO):
- Concentration and dosing solution formats (drug concentration ranges in ready-to-use IV liquids)
- Container and packaging (glass vs plastic, sealed container, compatibility/stability)
- Manufacturing format (premixed, no reconstitution/dilution vs concentrate requiring dilution)
- Sterilization approach (terminal sterilization and the method, including autoclave)
- Formulation parameters (pH windows, isotonicity with NaCl, salt form selection)
- Stability claims (percent decrease limits over a defined time in a defined container)
US 10,016,396 sits across buckets 2–5 with an added performance element (stability).
Competitive positioning risks
For competitors, risk rises sharply when a product aligns with all three of the following:
- sealed glass presentation,
- ready-to-use premixture positioning (no dilution or reconstitution), and
- stability marketing/spec consistent with the ≤2%/5-month requirement.
Even if concentration, pH, NaCl, and sterilization differ, Claim 1 exposure remains if the broad structural elements match.
What claim elements are most likely to be targeted in design-around attempts?
1) Break “ready-to-use premixture”
If a competitor supplies a formulation that requires dilution or reconstitution before administration (even if partially prepared), it can try to avoid the “no reconstitution or dilution required” limitation. This is the clearest conceptual design-around lever.
2) Break “sealed glass container”
Switching to a different container material or non-qualifying “sealed glass container” presentation is another direct lever. The patent does not merely say “stored in glass,” it specifies the composition is “disposed within a sealed glass container.”
3) Break stability in glass over five months
If a competitor’s product shows a concentration decrease greater than the claimed threshold under the claimed conditions, it may avoid Claim 9 even if other elements match.
4) Use different concentration, but still watch Claim 1
Avoiding Claims 2–5 is easier than avoiding Claim 1. The broad independent range is wide (0.005 to 50 μg/mL). A competitor must move outside that range to avoid Claim 1 concentration coverage.
5) Avoid autoclave terminal sterilization
Target Claims 15–16 by using non-autoclave manufacturing. This lever is less helpful against Claim 1 unless sterilization is already part of the product’s identity for the argument.
What does the claim drafting suggest about prosecution strategy?
The claim architecture uses:
- a broad independent window (Claim 1) for concentration and product form,
- dependent claims with progressively tighter concentration ranges,
- dependent claims with formulation parameters (NaCl, pH) and manufacturing constraints (terminal sterilization, autoclave),
- a storage-stability performance claim tied to container.
This structure is designed to support infringement theories across multiple formulation variants:
- If one variant misses an excipient/pH window, another dependent claim can capture it.
- If the opponent disputes chemical compatibility, the stability claim anchors performance-based infringement.
Key Takeaways
- US 10,016,396 claims a ready-to-use IV dexmedetomidine liquid premix in a sealed glass container, with 0.005 to 50 μg/mL drug concentration in Claim 1.
- Dependent claims lock additional parameters: narrower concentration bands, NaCl wt% (0.01 to 2.0 or ~0.9), specific total volumes (20/50/100 mL), ≤2% dexmedetomidine loss after 5 months in the glass container, hydrochloride salt, pH windows, and terminal sterilization by autoclave.
- The highest-leverage infringement elements for product risk are (i) ready-to-use without dilution/reconstitution, (ii) sealed glass container, and (iii) the 5-month glass stability performance.
- Design-around strategies should prioritize changing premix status, container/material, and stability outcome, since those map to the independent claim’s core limitations.
FAQs
-
Does Claim 1 require a specific pH?
No. pH appears only in dependent Claims 11–14.
-
Can a product avoid Claim 9 (stability) while still infringing Claim 1?
Yes. Claim 9 is dependent; infringement of Claim 1 can still occur if the independent elements are met.
-
Is autoclave mandatory to infringe the patent?
Autoclave is only in dependent Claim 16. Claim 1 does not require the autoclave limitation.
-
If a competitor uses a different dexmedetomidine salt, does it avoid the patent?
Not automatically. Claim 1 covers “dexmedetomidine or a pharmaceutically acceptable salt.” Avoiding Claim 10 (hydrochloride) does not avoid Claim 1.
-
Which claim element is the most direct design-around lever?
The “ready to use premixture that does not require reconstitution or dilution prior to administration” limitation (and the “sealed glass container” limitation) directly target product form.
References
[1] US Patent No. 10,016,396. (n.d.). Claims provided in user prompt.
